naa a22 4500 510763790 CHVBK 20180411083149.0 cr unu---uuuuu 180411e20131001xx s 000 0 eng 10.1007/s12094-013-1008-2 doi (NATIONALLICENCE)springer-10.1007/s12094-013-1008-2 Treatment outcome for patients with primary NSCLC and synchronous solitary metastasis [Elektronische Daten] [Q. Xu, Y. Wang, H. Liu, S. Meng, S. Zhou, J. Xu, G. Schmid-Bindert, C. Zhou] Introduction: Non-small cell lung cancer (NSCLC) patients with synchronous solitary metastasis were generally considered as stage IV and believed to be incurable. Recently, growing evidence has indicated that surgical treatment may provide these patients with a survival benefit. The aim of this study was to retrospectively analyze the effectiveness of different treatments for primary tumors and solitary metastases. Materials and methods: Patients older than 18years with histologically confirmed stage IV NSCLC and a confirmed synchronous solitary metastasis that diagnosed within 2months of primary NSCLC. Patients with uncontrolled massive pleural effusion were excluded. Between February 2002 and October 2010, 213 patients were considered eligible and enrolled in this cohort. Results: The median survival time (MST) for the 213 patients was 12.6months. Forty-five patients received primary pulmonary tumor surgery in the entire cohort. The MSTs of patients who received primary tumor resection and those who did not were 31.8 and 11.4months (p<0.01). The MST of the patients with solitary brain metastasis was 12.3months. Forty-one patients who received brain surgical treatment or SRS had a MST of 15.4months and others who only received WBRT had a MST of 11.5months (p=0.002). Gender, the stage of the primary tumor, PS and whether the primary tumor was removed all affected prognosis independently. Conclusions: Aggressive local and metastasis treatments could lead to better clinical outcomes and thus provide an option for clinicians in the future management of patients with NSCLC and synchronous solitary metastasis. Federación de Sociedades Españolas de Oncología (FESEO), 2013 Treatment outcome nationallicence Non-small cell lung cancer nationallicence Solitary metastasis nationallicence Thoracic surgery nationallicence Prognostic factors nationallicence Xu Q. Department of Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, 507 Zhengmin Road, 200433, Shanghai, People's Republic of China aut Wang Y. Department of Respiratory Medicine, Drum Tower Hospital, Medical School of Nanjing University, 210008, Nanjing, Jiangsu, People's Republic of China aut Liu H. Department of Radiation Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, 200433, Shanghai, People's Republic of China aut Meng S. Department of Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, 507 Zhengmin Road, 200433, Shanghai, People's Republic of China aut Zhou S. Department of Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, 507 Zhengmin Road, 200433, Shanghai, People's Republic of China aut Xu J. Department of Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, 507 Zhengmin Road, 200433, Shanghai, People's Republic of China aut Schmid-Bindert G. Interdisciplinary Thoracic Oncology, University Medical Center Mannheim, Heidelberg University, 68167, Mannheim, Germany aut Zhou C. Department of Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, 507 Zhengmin Road, 200433, Shanghai, People's Republic of China aut Clinical and Translational Oncology Springer Milan 15/10(2013-10-01), 802-809 1699-048X 15:10<802 2013 15 12094 https://doi.org/10.1007/s12094-013-1008-2 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-013-1008-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Xu Q. Department of Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, 507 Zhengmin Road, 200433, Shanghai, People's Republic of China aut NATIONALLICENCE 700 1- Wang Y. Department of Respiratory Medicine, Drum Tower Hospital, Medical School of Nanjing University, 210008, Nanjing, Jiangsu, People's Republic of China aut NATIONALLICENCE 700 1- Liu H. Department of Radiation Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, 200433, Shanghai, People's Republic of China aut NATIONALLICENCE 700 1- Meng S. Department of Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, 507 Zhengmin Road, 200433, Shanghai, People's Republic of China aut NATIONALLICENCE 700 1- Zhou S. Department of Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, 507 Zhengmin Road, 200433, Shanghai, People's Republic of China aut NATIONALLICENCE 700 1- Xu J. Department of Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, 507 Zhengmin Road, 200433, Shanghai, People's Republic of China aut NATIONALLICENCE 700 1- Schmid-Bindert G. Interdisciplinary Thoracic Oncology, University Medical Center Mannheim, Heidelberg University, 68167, Mannheim, Germany aut NATIONALLICENCE 700 1- Zhou C. Department of Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, 507 Zhengmin Road, 200433, Shanghai, People's Republic of China aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/10(2013-10-01), 802-809 1699-048X 15:10<802 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer